Nuventra Pharma Sciences

Nuventra is the pharmaceutical industry’s go-to resource for clinical pharmacology, pharmacokinetic, and pharmacometric consulting services.

[Nuventra Pharma Sciences @Nuventra]

In May of 2021, Nuventra became part of CATO SMS and we‘re excited to share that we unveiled our new name, Allucent! Read more about our new name and how it reflects our focus on helping small and mid-sized #biotech companies #bringnewtherapiestolight: https://t.co/7FtGEmbnTb

[Nuventra Pharma Sciences @Nuventra]

Now part of @Allucent_CRO — built with one thing in mind: to solve the distinct challenges of small and mid-sized #biotechs. One way we do that is with our model-informed drug development (MIDD) services. Follow us at @Allucent_CRO to learn more. https://t.co/mA9G5kFbNR

[Nuventra Pharma Sciences @Nuventra]

Now @Allucent_CRO we’re purposefully built to support small and mid-sized #biotechs. With expertise in clinical pharmacology and modeling, we translate complex data into actionable insights across the entire drug development spectrum. https://t.co/4IRtUioPPI

[Nuventra Pharma Sciences @Nuventra]

Now part of @Allucent_CRO we’re applying our expertise in clinical pharmacology and modeling to help guide crucial drug development decisions for #biotechs worldwide. Follow us at @Allucent_CRO to learn more. https://t.co/krUnYZW8aA

[Nuventra Pharma Sciences @Nuventra]

Nuventra is proud to be part of @Allucent_CRO! As 2022 comes to a close, we will no longer be posting on Nuventra’s LinkedIn page. Please follow us at @Allucent_CRO to stay up to date with our latest content and news! https://t.co/7t0ZsRMVe6

#biotech #cro

[Nuventra Pharma Sciences @Nuventra]

Regulatory authorities continue to stress the importance of inclusive clinical trials for promoting drug safety across diverse patient groups. Learn more about clinical trial diversity and how to promote inclusivity in our blog:
https://t.co/68ub1dXzuc

[Nuventra Pharma Sciences @Nuventra]

Modeling techniques, such as popPK, extrapolation, & clinical trial simulations, can help solve unique challenges of #pediatricdrugdevelopment by optimizing trial designs & reducing some burdens on pediatric patients. Learn more: https://t.co/QKSUb1WBkA

[Nuventra Pharma Sciences @Nuventra]

#Oligonucleotide therapeutics are cutting-edge #genetictherapies that can achieve long-lasting or even curative effects by inhibiting, replacing, or altering genes. Learn more about what these therapies are & how they work in our latest blog: https://t.co/FbiIyghCZe

[Nuventra Pharma Sciences @Nuventra]

Pharmacokinetic (PK) studies aim to understand how drugs move throughout and interact with the body by examining the processes of absorption, distribution, metabolism, and excretion (ADME). Learn more about PK in our latest blog: https://t.co/iQuLxdFSqN

[Nuventra Pharma Sciences @Nuventra]

Are you interested in receiving content from Nuventra? Sign up to receive the latest blogs, webinars, events, and more directly to your inbox: https://t.co/N6VLlFH9QI
Nuventra is now part of @CATO_SMS.

[Nuventra Pharma Sciences @Nuventra]

Did you miss our recent webinar, “Concentration-QT Analysis: Saving Time and Resources with Modeling?” Access this presentation and watch all of Nuventra’s past webinars on our webinar library: https://t.co/zzVra58RzZ

[Nuventra Pharma Sciences @Nuventra]

Attention: Nuventra does not send any unsolicited offers for employment. It's been brought to our attention that someone is impersonating Nuventra’s HR team. If you receive an unsolicited job offer, please do not respond to it & do not send any personal or financial information.

[Nuventra Pharma Sciences @Nuventra]

Nuventra is pleased to welcome Dr. Nitin Kaila as Senior Director of Pharmacometrics. Dr. Kaila has extensive experience with dose selection, clinical trial design, and planning and executing various modeling activities. Learn more: https://t.co/k1xgwazHI6

[Nuventra Pharma Sciences @Nuventra]

It is critical to understand both the sources and types of PK data that will be used in analyses (such as NCA) as well as the specific formatting and dataset requirements that are part of a #CDISC submission package. Learn more in our blog: https://t.co/dTpGI7OZRA

[Nuventra Pharma Sciences @Nuventra]

Compartmental PK modeling can range in complexity from one compartment to hundreds of compartments. Each type has its own applications and advantages. Learn more about the different types of compartmental models in our blog: https://t.co/oNsWS4EfAu

[Nuventra Pharma Sciences @Nuventra]

One of the most common #clinicalpharmacology mistakes is simply not taking full advantage of what the field has to offer. If done properly, clinical pharmacology can serve as a roadmap to successful approval. Learn more in the blog: https://t.co/KE1YTvzVBZ

[Nuventra Pharma Sciences @Nuventra]

We are proud to announce that Nuventra’s scientists authored the most-downloaded article of 2021 in @ASCPTjournals', Clinical Pharmacology & Therapeutics. The article has been downloaded over 85,000 times. Read the article here: https://t.co/9Jxr2yhInP

[Nuventra Pharma Sciences @Nuventra]

Determining the first-in-human (FIH) dose for clinical studies is a challenging endeavor with inherent uncertainty. Understand what methods are available & other key considerations for selecting a safe FIH dose in our blog: https://t.co/DVxjni2ZuI

[Nuventra Pharma Sciences @Nuventra]

Modeling and simulation is a key tool in leveraging existing data to support a 505(b)(2) application. With modeling, different release profiles, formulations, or routes of administration can be explored. Learn more in the blog: https://t.co/DTggni1Th4

[Nuventra Pharma Sciences @Nuventra]

Join us on March 24th at 1pm ET for a #webinar discussing the benefits of Concentration-QT analysis, an internationally accepted, low-cost, and efficient approach compared to conducting a thorough QT study. Register here: https://t.co/Lu91FLJQEx